ASCO: Extension of Aromatase Inhibitor Tx Benefits Breast CA

This article originally appeared here.
Share this content:
ASCO: Extension of Aromatase Inhibitor Tx Benefits Breast CA
ASCO: Extension of Aromatase Inhibitor Tx Benefits Breast CA

MONDAY, June 6, 2016 (HealthDay News) -- For postmenopausal women with breast cancer, extension of treatment with an aromatase inhibitor to 10 years is associated with improved outcomes, according to a study published online June 5 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago.

Paul E. Goss, M.D., Ph.D., from Massachusetts General Hospital Cancer Center in Boston, and colleagues conducted a double-blind placebo-controlled trial to examine the effect of extended letrozole for an additional five years in a cohort of 1,918 postmenopausal women.

The researchers found that the five-year disease-free survival rate was 95 and 91 percent in the letrozole and placebo groups, respectively (hazard ratio for recurrence or occurrence of contralateral breast cancer, 0.66; P = 0.01). Five-year overall survival was 93 and 94 percent, respectively (hazard ratio, 0.97; P = 0.83). The annual incidence rate of contralateral breast cancer was 0.21 and 0.49 percent in the letrozole and placebo groups (hazard ratio, 0.42; P = 0.007). Patients receiving letrozole more often had bone-related toxic effects.

"The risk of disease recurrence and contralateral breast cancer was significantly lower among women who continued aromatase inhibitor for 10 years than among women who received placebo after the initial five years of aromatase-inhibitor therapy," the authors write. However, "the rate of overall survival was not higher with the aromatase inhibitor than with placebo."

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures letrozole and contributed funding to the study.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »